Rating Change
Baird analysts reiterated a Outperform rating on Larimar Therapeutics, Inc. (NASDAQ:LRMR) on June 30, 2026.
reiterateNASDAQ:LRMR
Baird Reiterates Outperform Rating on Larimar Therapeutics, Inc. (LRMR)
Rating Change Baird analysts reiterated a Outperform rating on Larimar Therapeutics, Inc. (NASDAQ:LRMR) on June 30, 2026. Market Context Larimar Therapeutics, Inc.
Market Context
Larimar Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $3.05 with a market capitalization of $343.6M.
Analyst coverage from Baird provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Larimar Therapeutics, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Larimar Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jun 30, 2026 | Baird | Outperform | N/A |
| May 27, 2026 | JP Morgan | Overweight | N/A |
| May 18, 2026 | Wedbush | Outperform | N/A |
| Mar 20, 2026 | Wedbush | Outperform | N/A |
| Mar 03, 2026 | Wedbush | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View LRMR Stock Page
Frequently Asked Questions
What does a Outperform rating mean for LRMR?
A Outperform rating from Baird reflects the analyst's outlook on Larimar Therapeutics, Inc. (NASDAQ:LRMR). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the LRMR forecast page.